Ampicillin-Sulbactam Dosing for CRAB
For severe CRAB infections, use high-dose sulbactam at 9-12 g/day divided into 3-4 doses, with each dose administered as a 4-hour infusion. This represents the sulbactam component only; when given as ampicillin-sulbactam, this translates to 18-24 g/day of the combination product 1.
Dosing Algorithm Based on Infection Severity and MIC
Standard Dosing (Most CRAB Infections)
- Sulbactam 3 g every 8 hours as a 4-hour infusion (9 g/day total)
- This provides optimal pharmacodynamic targets for isolates with MIC ≤4 mg/L 1
- The 4-hour extended infusion is critical for achieving adequate time above MIC 1
High-Dose Regimen (Severe Infections or Higher MIC)
- Sulbactam 3-4 g every 6-8 hours (up to 12 g/day)
- Consider for isolates with MIC 8 mg/L (intermediate susceptibility) 2
- The most recent 2023 guideline specifically states: "The dose of sulbactam can be increased to 6.0-9.0 g/d for severe CRAB infections" 2
Critical Considerations for Susceptibility
- Only use if sulbactam MIC ≤4 mg/L - this is the accepted susceptibility threshold 1
- For MIC 8 mg/L, high-dose extended infusion (3 g q8h over 4 hours) achieves >90% probability of target attainment 3
- Do not use as monotherapy for isolates resistant to both sulbactam and meropenem - these require 3 times higher exposures and even high-dose regimens provide inadequate coverage 4
Combination Therapy Requirements
Sulbactam should NOT be used as monotherapy for CRAB 1. The 2023 guideline explicitly recommends sulbactam-containing combinations augmented with:
- Tigecycline
- Polymyxin (colistin or polymyxin B)
- Doxycycline or minocycline
- Based on antimicrobial susceptibility testing 2
Recent evidence supports ampicillin-sulbactam combined with tigecycline or polymyxin as superior to polymyxin-based regimens alone, with lower nephrotoxicity (15.3% vs 33%) and comparable or better clinical outcomes 1.
Site-Specific Considerations
Pulmonary Infections (VAP/Pneumonia)
- High-dose sulbactam 9-12 g/day in combination therapy is preferred 2, 1
- ELF penetration requires higher dosing: standard 1 g q6h only achieves >90% PTA up to MIC 2 mg/L in lung tissue (versus 4 mg/L in plasma) 3
- Ampicillin-sulbactam showed better microbiologic cure rates than colistin in VAP (day 7 eradication) 1
Bloodstream Infections
- Standard to high-dose regimens (9-12 g/day) in combination 2
- One study showed significantly lower 28-day mortality with cefoperazone-sulbactam versus other regimens in CRAB bacteremia 2
CNS Infections (Meningitis)
- High-dose intravenous ampicillin-sulbactam combined with intraventricular colistin 5
- Note: Two meningitis cases treated with ampicillin-sulbactam alone failed in one series 6, emphasizing need for combination therapy
Renal Dose Adjustment
Per FDA labeling 7:
- CrCl ≥30 mL/min: No adjustment needed (standard dosing q6-8h)
- CrCl 15-29 mL/min: Reduce to q12h dosing
- CrCl 5-14 mL/min: Reduce to q24h dosing
Critical Pitfalls to Avoid
Using standard FDA-approved dosing (1 g sulbactam q6h) - This is inadequate for severe CRAB infections. The FDA label 7 lists maximum 4 g/day sulbactam, but expert guidelines explicitly recommend 9-12 g/day for CRAB 1
Short infusions - Standard 10-15 minute infusions are suboptimal. Use 4-hour infusions for severe infections 1
Monotherapy - Never use sulbactam alone for CRAB; always combine with another active agent 2, 1
Ignoring MIC values - Efficacy drops dramatically when sulbactam MIC >4 mg/L or when isolates are resistant to both sulbactam and meropenem 4
Penicillin allergy - Sulbactam-containing combinations are contraindicated in penicillin-hypersensitive patients 2
Evidence Quality Context
The 2023 guideline 2 provides the most recent recommendations (weak recommendation, low-quality evidence from RCTs showing reduced mortality RR 0.77, treatment failure RR 0.72, and pathogen eradication failure RR 0.49 versus polymyxin-based therapy). The 2015 ICU task force guidelines 1 provide consistent dosing recommendations (BII level evidence) based on PK/PD studies and comparative effectiveness data showing ampicillin-sulbactam comparable or superior to colistin with better safety profile.